|On-demand preexposure prophylaxis in men at high risk for HIV-1 infection|
JM Molina, C Capitant, B Spire, G Pialoux, L Cotte, I Charreau, ...
N Engl J Med 373, 2237-2246, 2015
|Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment|
L Ferradini, A Jeannin, L Pinoges, J Izopet, D Odhiambo, L Mankhambo, ...
The lancet 367 (9519), 1335-1342, 2006
|Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach|
B Spire, S Duran, M Souville, C Leport, F Raffi, JP Moatti
Social science & medicine 54 (10), 1481-1496, 2002
|Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light|
B Spire, F Barre-Sinoussi, D Dormont, L Montagnier, JC Chermann
The Lancet 325 (8422), 188-189, 1985
|Inactivation of lymphadenopathy associated virus by chemical disinfectants|
B Spire, L Montagnier, F Barre-Sinoussi, JC Chermann
The Lancet 324 (8408), 899-901, 1984
|Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy|
S Duran, M Savès, B Spire, V Cailleton, A Sobel, P Carrieri, D Salmon, ...
Aids 15 (18), 2441-2444, 2001
|International AIDS Society global scientific strategy: towards an HIV cure 2016|
SG Deeks, SR Lewin, AL Ross, J Ananworanich, M Benkirane, P Cannon, ...
Nature medicine 22 (8), 839, 2016
|Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment|
JP Moatti, MP Carrieri, B Spire, JA Gastaut, JP Cassuto, J Moreau, ...
Aids 14 (2), 151-155, 2000
|Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART|
S Duran, B Spire, F Raffi, V Walter, D Bouhour, V Journot, V Cailleton, ...
HIV clinical trials 2 (1), 38-45, 2001
|Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study|
JM Molina, I Charreau, B Spire, L Cotte, J Chas, C Capitant, C Tremblay, ...
The lancet HIV 4 (9), e402-e410, 2017
|The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort|
P Carrieri, V Cailleton, V Le Moing, B Spire, P Dellamonica, E Bouvet, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 28 (3), 232-239, 2001
|Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme.|
M BouHamdan, S Benichou, F Rey, JM Navarro, I Agostini, B Spire, ...
Journal of virology 70 (2), 697-704, 1996
|On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial|
JM Molina, C Capitant, B Spire, G Pialoux, C Chidiac, I Charreau, ...
Conference on retroviruses and opportunistic infections 2015, 2015
|Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome|
W Rozenbaum, D Dormont, B Spire, E Vilmer, M Gentilini, C Griscelli, ...
The Lancet 325 (8426), 450-451, 1985
|Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy|
AD Bouhnik, M Préau, E Vincent, MP Carrieri, H Gallais, G Lepeu, ...
Antivir ther 10 (1), 53-61, 2005
|Health-related quality of life after 1 year of highly active antiretroviral therapy|
P Carrieri, B Spire, S Duran, C Katlama, D Peyramond, C François, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 32 (1), 38-47, 2003
|Nonadherence among HIV-infected injecting drug users: the impact of social instability.|
AD Bouhnik, M Chesney, P Carrieri, H Gallais, J Moreau, JP Moatti, ...
Journal of acquired immune deficiency syndromes (1999) 31, S149-53, 2002
|Characterization of the RNA dependent DNA polymerase of a new human T lymphotropic retrovirus (lymphadenopathy associated virus)|
MA Rey, B Spire, D Dormont, F Barre-Sinoussi, L Montagnier, ...
Biochemical and biophysical research communications 121 (1), 126-133, 1984
|Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST)|
B Spire, GM Lucas, MP Carrieri
International Journal of Drug Policy 18 (4), 262-270, 2007
|The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB|
I Agostini, JM Navarro, F Rey, M Bouhamdan, B Spire, R Vigne, J Sire
Journal of molecular biology 261 (5), 599-606, 1996